Bulletin
Investor Alert

Perrigo Co. PLC

NYS: PRGO

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 15, 2021, 4:40 p.m.

/zigman2/quotes/201110862/composite

$

44.72

Change

0.00 0.00%

Volume

Volume 13,847

Quotes are delayed by 20 min

/zigman2/quotes/201110862/composite

Previous close

$ 45.47

$ 44.72

Change

-0.75 -1.65%

Day low

Day high

$44.69

$45.70

Open

52 week low

52 week high

$38.20

$50.90

Open

Company Description

Perrigo Co. Plc provides self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company was founded by Luther Perrigo in 1887 and is headquartered ...

Perrigo Co. Plc provides self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Valuation

Price to Sales Ratio

1.20

Price to Book Ratio

1.05

Price to Cash Flow Ratio

9.57

Enterprise Value to EBITDA

10.64

Enterprise Value to Sales

1.82

Total Debt to Enterprise Value

0.41

Efficiency

Revenue/Employee

440,261.00

Income Per Employee

-14,139.00

Receivables Turnover

4.32

Total Asset Turnover

0.44

Liquidity

Current Ratio

2.27

Quick Ratio

1.40

Cash Ratio

0.47

Profitability

Gross Margin

35.77

Operating Margin

9.13

Pretax Margin

-2.95

Net Margin

-3.21

Return on Assets

-1.43

Return on Equity

-2.84

Return on Total Capital

4.94

Return on Invested Capital

-1.75

Capital Structure

Total Debt to Total Equity

66.48

Total Debt to Total Capital

39.93

Total Debt to Total Assets

32.72

Long-Term Debt to Equity

65.21

Long-Term Debt to Total Capital

39.17

Officers and Executives

Name Age Officer Since Title
Mr. Murray S. Kessler 60 2018 President, Chief Executive Officer & Director
Mr. Raymond P. Silcock 69 2019 CFO, Principal Accounting Officer & Executive VP
Mr. Thomas Farrington 61 2006 Chief Information Officer & Senior Vice President
Dr. Grainne Quinn 49 2014 Chief Medical Officer & Executive Vice President
Mr. Adrian Innergård 40 - General Manager-Northern Europe

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/12/2021 Katherine C. Doyle
Director
2,706   Derivative/Non-derivative trans. at $41.28 per share. 111,703
08/12/2021 Katherine C. Doyle
Director
5,637   Derivative/Non-derivative trans. at $41.28 per share. 232,695
05/07/2021 Theodore Rapp Samuels
Director
5,804   Derivative/Non-derivative trans. at $42.96 per share. 249,339
05/07/2021 Geoffrey M. Parker
Director
5,804   Derivative/Non-derivative trans. at $42.96 per share. 249,339
05/07/2021 Donal M. O'Connor
Director
5,804   Derivative/Non-derivative trans. at $42.96 per share. 249,339
05/07/2021 Rolf Allan Classon
Director
7,255   Derivative/Non-derivative trans. at $42.96 per share. 311,674
05/07/2021 Bradley A. Alford
Director
5,804   Derivative/Non-derivative trans. at $42.96 per share. 249,339
05/07/2021 Jeffrey B. Kindler
Director
5,804   Derivative/Non-derivative trans. at $42.96 per share. 249,339
05/07/2021 Adriana Karaboutis
Director
5,804   Derivative/Non-derivative trans. at $42.96 per share. 249,339
05/07/2021 Erica L. Mann
Director
5,804   Derivative/Non-derivative trans. at $42.96 per share. 249,339
05/07/2021 Geoffrey M. Parker
Director
2,786   Derivative/Non-derivative trans. at $42.96 per share. 119,686
05/07/2021 Donal M. O'Connor
Director
2,786   Derivative/Non-derivative trans. at $42.96 per share. 119,686
05/07/2021 Rolf Allan Classon
Director
3,483   Derivative/Non-derivative trans. at $42.96 per share. 149,629
05/07/2021 Bradley A. Alford
Director
2,786   Derivative/Non-derivative trans. at $42.96 per share. 119,686
05/07/2021 Jeffrey B. Kindler
Director
2,786   Derivative/Non-derivative trans. at $42.96 per share. 119,686
05/07/2021 Adriana Karaboutis
Director
2,786   Derivative/Non-derivative trans. at $42.96 per share. 119,686
05/07/2021 Erica L. Mann
Director
3,019   Derivative/Non-derivative trans. at $42.96 per share. 129,696
04/05/2021 Raymond P. Silcock
EVP, Chief Financial Officer
3,964   Derivative/Non-derivative trans. at $40.39 per share. 160,105
03/17/2021 Geoffrey M. Parker
Director
2,500   Acquisition at $41.29 per share. 103,225
03/10/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
2,662   Disposition at $41.23 per share. 109,754
03/08/2021 Todd W. Kingma
Executive VP, General Counsel
2,166   Derivative/Non-derivative trans. at $41.82 per share. 90,582
03/08/2021 Thomas M. Farrington
EVP and CIO
1,639   Derivative/Non-derivative trans. at $41.82 per share. 68,542
03/08/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
1,179   Derivative/Non-derivative trans. at $41.82 per share. 49,305
03/08/2021 Svend D. Andersen
EVP & President CHCI
47   Derivative/Non-derivative trans. at $41.82 per share. 1,965
03/08/2021 Grainne Quinn
EVP, Chief Medical Officer
1,083   Derivative/Non-derivative trans. at $41.82 per share. 45,291
03/08/2021 Robert Willis
EVP & CHRO
363   Derivative/Non-derivative trans. at $41.82 per share. 15,180
03/08/2021 Robert Willis
EVP & CHRO
980   Derivative/Non-derivative trans. at $41.82 per share. 40,983
03/08/2021 Todd W. Kingma
Executive VP, General Counsel
7,571   Award at $41.82 per share. 316,619
03/08/2021 Sharon Kochan
EVP & President Rx
4,721   Award at $41.82 per share. 197,432
03/08/2021 Thomas M. Farrington
EVP and CIO
3,758   Award at $41.82 per share. 157,159
03/08/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
4,121   Award at $41.82 per share. 172,340
03/08/2021 Svend D. Andersen
EVP & President CHCI
5,543   Award at $41.82 per share. 231,808
03/08/2021 Grainne Quinn
EVP, Chief Medical Officer
2,082   Award at $41.82 per share. 87,069
03/08/2021 Robert Willis
EVP & CHRO
1,884   Award at $41.82 per share. 78,788
03/08/2021 Robert Willis
EVP & CHRO
697   Derivative/Non-derivative trans. at $41.82 per share. 29,148
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
667   Derivative/Non-derivative trans. at $41.04 per share. 27,373
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
777   Derivative/Non-derivative trans. at $41.04 per share. 31,888
03/05/2021 Murray S. Kessler
CEO; Director
5,683   Derivative/Non-derivative trans. at $41.04 per share. 233,230
03/05/2021 Murray S. Kessler
CEO; Director
6,622   Derivative/Non-derivative trans. at $41.04 per share. 271,766
03/05/2021 Murray S. Kessler
CEO; Director
6,623   Derivative/Non-derivative trans. at $41.04 per share. 271,807
03/05/2021 Thomas M. Farrington
EVP and CIO
640   Derivative/Non-derivative trans. at $41.04 per share. 26,265
03/05/2021 Thomas M. Farrington
EVP and CIO
607   Derivative/Non-derivative trans. at $41.04 per share. 24,911
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
442   Derivative/Non-derivative trans. at $41.04 per share. 18,139
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
514   Derivative/Non-derivative trans. at $41.04 per share. 21,094
03/05/2021 Svend D. Andersen
EVP & President CHCI
37   Derivative/Non-derivative trans. at $41.04 per share. 1,518
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
570   Derivative/Non-derivative trans. at $41.04 per share. 23,392
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
666   Derivative/Non-derivative trans. at $41.04 per share. 27,332
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
548   Derivative/Non-derivative trans. at $41.04 per share. 22,489
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
638   Derivative/Non-derivative trans. at $41.04 per share. 26,183
03/05/2021 Robert Willis
EVP & CHRO
496   Derivative/Non-derivative trans. at $41.04 per share. 20,355
03/05/2021 Robert Willis
EVP & CHRO
286   Derivative/Non-derivative trans. at $41.04 per share. 11,737
03/05/2021 Robert Willis
EVP & CHRO
302   Derivative/Non-derivative trans. at $41.04 per share. 12,394
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
2,540   Derivative/Non-derivative trans. at $41.04 per share. 104,241
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
2,960   Derivative/Non-derivative trans. at $41.04 per share. 121,478
03/05/2021 Murray S. Kessler
CEO; Director
14,061   Derivative/Non-derivative trans. at $41.04 per share. 577,063
03/05/2021 Murray S. Kessler
CEO; Director
16,385   Derivative/Non-derivative trans. at $41.04 per share. 672,440
03/05/2021 Murray S. Kessler
CEO; Director
14,061   Derivative/Non-derivative trans. at $41.04 per share. 577,063
03/05/2021 Murray S. Kessler
CEO; Director
16,385   Derivative/Non-derivative trans. at $41.04 per share. 672,440
03/05/2021 Sharon Kochan
EVP & President Rx
1,996   Derivative/Non-derivative trans. at $41.04 per share. 81,915
03/05/2021 Sharon Kochan
EVP & President Rx
2,061   Derivative/Non-derivative trans. at $41.04 per share. 84,583
03/05/2021 Thomas M. Farrington
EVP and CIO
1,261   Derivative/Non-derivative trans. at $41.04 per share. 51,751
03/05/2021 Thomas M. Farrington
EVP and CIO
1,469   Derivative/Non-derivative trans. at $41.04 per share. 60,287
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
1,542   Derivative/Non-derivative trans. at $41.04 per share. 63,283
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
1,797   Derivative/Non-derivative trans. at $41.04 per share. 73,748
03/05/2021 Svend D. Andersen
EVP & President CHCI
2,540   Derivative/Non-derivative trans. at $41.04 per share. 104,241
03/05/2021 Svend D. Andersen
EVP & President CHCI
2,960   Derivative/Non-derivative trans. at $41.04 per share. 121,478
03/05/2021 Richard S. Sorota
EVP & President CSCA
2,540   Derivative/Non-derivative trans. at $41.04 per share. 104,241
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
1,996   Derivative/Non-derivative trans. at $41.04 per share. 81,915
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
2,326   Derivative/Non-derivative trans. at $41.04 per share. 95,459
03/05/2021 Raymond P. Silcock
EVP, Chief Financial Officer
3,629   Derivative/Non-derivative trans. at $41.04 per share. 148,934
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
1,053   Derivative/Non-derivative trans. at $41.04 per share. 43,215
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
1,226   Derivative/Non-derivative trans. at $41.04 per share. 50,315
03/05/2021 Robert Willis
EVP & CHRO
953   Derivative/Non-derivative trans. at $41.04 per share. 39,111
03/05/2021 Robert Willis
EVP & CHRO
550   Derivative/Non-derivative trans. at $41.04 per share. 22,572
03/05/2021 Robert Willis
EVP & CHRO
580   Derivative/Non-derivative trans. at $41.04 per share. 23,803
03/05/2021 Murray S. Kessler
CEO; Director
5,683   Derivative/Non-derivative trans. at $41.04 per share. 233,230
03/05/2021 Svend D. Andersen
EVP & President CHCI
55   Derivative/Non-derivative trans. at $41.04 per share. 2,257
03/05/2021 Richard S. Sorota
EVP & President CSCA
1,108   Derivative/Non-derivative trans. at $41.04 per share. 45,472
02/05/2021 James E. Dillard
EVP, Chief Scientific Officer
1,396   Derivative/Non-derivative trans. at $43.09 per share. 60,153
02/05/2021 James E. Dillard
EVP, Chief Scientific Officer
4,297   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2021 Richard S. Sorota
EVP & President CSCA
7,513   Acquisition at $43.48 per share. 326,665
11/09/2020 Theodore Rapp Samuels
Director
4,500   Acquisition at $46.91 per share. 211,095
11/09/2020 Rolf Allan Classon
Director
2,137   Acquisition at $46.75 per share. 99,904
/news/latest/company/us/prgo

MarketWatch News on PRGO

  1. Perrigo upgraded to outperform from market perform at Raymond James

    7:21 a.m. Oct. 14, 2021

    - Tomi Kilgore

  2. The Stock Market Had a Miserable September. What’s Coming Next.

    4:47 p.m. Sept. 30, 2021

    - Jacob Sonenshine

  3. Perrigo expects deal to close by end of first half of 2022

    6:45 a.m. Sept. 8, 2021

    - Ciara Linnane

  4. Perrigo expects deal to add about EUR400 mln in net sales in full-year 2023

    6:43 a.m. Sept. 8, 2021

    - Ciara Linnane

  5. Perrigo expects deal to add about $1 to adj. EPS in full-year 2023

    6:43 a.m. Sept. 8, 2021

    - Ciara Linnane

  6. Perrigo to acquire consumer self-care company HRA Pharma for about $2.1 bln in cash

    6:43 a.m. Sept. 8, 2021

    - Ciara Linnane

  7. Match stock rallies on inclusion to S&P 500 in reshuffling

    6:09 p.m. Sept. 3, 2021

    - Wallace Witkowski

  8. Dow, S&P Close at All-Time Highs Again

    12:49 p.m. Aug. 11, 2021

    - Pierre Briançon,

  9. Perrigo Stock Slides Because Fewer People Got Colds This Year

    10:29 a.m. Aug. 11, 2021

    - Teresa Rivas

  10. CORRECTED: Perrigo Q2 loss per share 84 cents vs. EPS 9 cents a year ago

    7:00 a.m. Aug. 11, 2021

    - Ciara Linnane

  11. Perrigo shares slide 2.3% premarket

    6:39 a.m. Aug. 11, 2021

    - Ciara Linnane

  12. Perrigo sees FY21 adj. EPS at low end of range of $2.50 to $2.70

    6:39 a.m. Aug. 11, 2021

    - Ciara Linnane

  13. Perrigo Q2 sales $981 mln vs. $948.8 mln a year ago; FactSet consensus $1.018 bln

    6:36 a.m. Aug. 11, 2021

    - Ciara Linnane

  14. Loading more headlines...
/news/nonmarketwatch/company/us/prgo

Other News on PRGO

  1. Why Perrigo Is Up More Than 10% Today

    1:40 p.m. Sept. 30, 2021

    - Motley Fool

  2. Perrigo (PRGO) Stock Up on Irish Tax Bill Settlement Deal

    10:44 a.m. Sept. 30, 2021

    - Zacks.com

  3. 2 Newsmaker Stocks Posting Big Gains Thursday Morning

    9:36 a.m. Sept. 30, 2021

    - Motley Fool

  4. Perrigo tax settlement prompts upgrade at Jefferies

    8:34 a.m. Sept. 30, 2021

    - Seeking Alpha

  5. SPCE, RIDE and FOLD among pre market gainers

    8:26 a.m. Sept. 30, 2021

    - Seeking Alpha

  6. Dividend Investing From Scratch: What If I Had To Start Over?

    12:35 p.m. Sept. 21, 2021

    - Seeking Alpha

  7. Dividend Champion Highlights: Week Of September 19

    11:50 p.m. Sept. 18, 2021

    - Seeking Alpha

  8. Why Is Perrigo (PRGO) Up 7.1% Since Last Earnings Report?

    11:30 a.m. Sept. 10, 2021

    - Zacks.com

  9. 8 F-Rated Stocks to Sell in September

    8:56 a.m. Sept. 10, 2021

    - InvestorPlace.com

  10. Keep an Eye on Wall Street’s Clean Medicine Experiment

    7:03 a.m. Sept. 9, 2021

    - Charley Grant

  11. Harmony Investor Slides_vFINAL

    12:36 p.m. Sept. 8, 2021

    - Seeking Alpha

  12. Loading more headlines...

At a Glance

Perrigo Co. Plc

The Sharp Building

Hogan Place

Dublin, Dublin 2

Phone

353 17094000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$5.06B

Net Income

$-162.60M

2020 Sales Growth

4.7%

Employees

11,500

/news/pressrelease/company/us/prgo

Press Releases on PRGO

  1. Global Scar Dressing Market Size, Share to Exhibit 14.8% CAGR Through 2025

    6:37 a.m. July 28, 2021

    - Market Insight Reports

  2. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/207505872/composite DISH+1.05%
  • /zigman2/quotes/204151124/composite CURE-1.23%
  • /zigman2/quotes/214908404/composite GFL+1.15%
  • /zigman2/quotes/204236046/composite DUST+1.32%
  • /zigman2/quotes/200683073/composite FRC+0.90%
X
Powered by StockTwits
Link to MarketWatch's Slice.